[Clinical and immunological predictors of Graves' orbitopathy after radioiodine therapy of Graves' disease].
Journal
Problemy endokrinologii
ISSN: 2308-1430
Titre abrégé: Probl Endokrinol (Mosk)
Pays: Russia (Federation)
ID NLM: 0140673
Informations de publication
Date de publication:
10 Nov 2023
10 Nov 2023
Historique:
received:
08
04
2023
accepted:
04
08
2023
revised:
04
08
2023
medline:
17
11
2023
pubmed:
16
11
2023
entrez:
16
11
2023
Statut:
epublish
Résumé
Data on the effect of 131I on the course of Graves' orbitopathy (GO) are contradictory. A number of studies indicate a deterioration in the course of GO against the background of RAIT, in other studies such a connection has not been established. Cytokines that regulate inflammation could potentially be biomarkers for assessing GO activity and predicting the course of GO after RAIT. The purpose of this study was to evaluate the dynamics of eye symptoms and analyze immunological parameters: cytokine TGF-β1 and cytokine receptors: sTNFα-R1, sTNFα-R2, sIL-2R, sIL-6R over time after RAIT, as possible predictors of GO activation. The study included 59 patients (118 orbits) with GD in the state of euthyroidism and subclinical hyperthyroidism and low active and inactive GO, aimed at conducting RAIT. Concentrations of cytokine TGF-β1, sTNFα-RI and sTNFα-R2, sIL-2R, sIL-6R, TSH receptor antibodies (rTSH-Ab), free thyroxine (FT4) and free triiodothyronine (FT3), -thyroid-stimulating hormone (TSH) in the blood serum were determined. Ultrasound examination of the thyroid gland, multispiral computed tomography (MSCT)/magnetic resonance imaging (MRI) of the orbits was performed. The examination was carried out 3, 6, 12 months after the RAIT. The deterioration of the course of the GO (1-2 points according to CAS) was noted after 3 months. (32.5%) and to a lesser degree after 6 and 12 months (13.2% and 8.45%, respectively). Dynamics were not noted, approximately, in the same number of patients (40.5%, 41.5%, 45.8%, respectively). An improvement in the course of the GO was noted after 6 and 12 months (45.3, 45.8, respectively). After 3 and 6 months, the achievement of hypothyroidism and a significant increase in the level of rTSH-Ab were noted. In the analysis of cytokines and their receptors a significant decrease in the level of TGF-β1 was noted after 3, 6 and 12 months. There was also a significant decrease in sTNF-R1 and sIL-2R at 3 and 6 months. The level of sTNFα-R2 significantly decreased 3 months after RAIT. The level of sIL-6R has not changed significantly. After 3 months in patients with positive dynamics of image intensification, the level of TGF-β1 did not significantly change compared with the level before RAIT, in patients with worsening of the course of GO or without dynamics, the level of TGF-β1 significantly decreased. After 6 months, there was the same trend, not reaching statistical significance. The IgG4 level and the IgG4/IgG ratio increased to 6 and 12 months, which corresponded to an increase in diplopia index. The main limiting factor in the conduct of RAIT is the activity of the autoimmune process in the orbits. Since patients with inactive (CAS 0-2) or low activity (CAS 3-4) GO were referred for RAIT, there was no pronounced activation of GO after RAIT. There was a slight deterioration in the course of GO by only 1-2 points according to CAS after 3 months. (32.5%) and to a lesser degree after 6 months (13.2%). In the study, it was found that the main predictors of the deterioration of the course of GO after RAIT are uncompensated hypothyroidism, a high level of rTSH-Ab and a decrease in the level of cytokine TGF-β1.
Sections du résumé
BACKGROUND
BACKGROUND
Data on the effect of 131I on the course of Graves' orbitopathy (GO) are contradictory. A number of studies indicate a deterioration in the course of GO against the background of RAIT, in other studies such a connection has not been established. Cytokines that regulate inflammation could potentially be biomarkers for assessing GO activity and predicting the course of GO after RAIT.
AIM
OBJECTIVE
The purpose of this study was to evaluate the dynamics of eye symptoms and analyze immunological parameters: cytokine TGF-β1 and cytokine receptors: sTNFα-R1, sTNFα-R2, sIL-2R, sIL-6R over time after RAIT, as possible predictors of GO activation.
MATERIALS AND METHODS
METHODS
The study included 59 patients (118 orbits) with GD in the state of euthyroidism and subclinical hyperthyroidism and low active and inactive GO, aimed at conducting RAIT. Concentrations of cytokine TGF-β1, sTNFα-RI and sTNFα-R2, sIL-2R, sIL-6R, TSH receptor antibodies (rTSH-Ab), free thyroxine (FT4) and free triiodothyronine (FT3), -thyroid-stimulating hormone (TSH) in the blood serum were determined. Ultrasound examination of the thyroid gland, multispiral computed tomography (MSCT)/magnetic resonance imaging (MRI) of the orbits was performed. The examination was carried out 3, 6, 12 months after the RAIT.
RESULTS
RESULTS
The deterioration of the course of the GO (1-2 points according to CAS) was noted after 3 months. (32.5%) and to a lesser degree after 6 and 12 months (13.2% and 8.45%, respectively). Dynamics were not noted, approximately, in the same number of patients (40.5%, 41.5%, 45.8%, respectively). An improvement in the course of the GO was noted after 6 and 12 months (45.3, 45.8, respectively). After 3 and 6 months, the achievement of hypothyroidism and a significant increase in the level of rTSH-Ab were noted. In the analysis of cytokines and their receptors a significant decrease in the level of TGF-β1 was noted after 3, 6 and 12 months. There was also a significant decrease in sTNF-R1 and sIL-2R at 3 and 6 months. The level of sTNFα-R2 significantly decreased 3 months after RAIT. The level of sIL-6R has not changed significantly. After 3 months in patients with positive dynamics of image intensification, the level of TGF-β1 did not significantly change compared with the level before RAIT, in patients with worsening of the course of GO or without dynamics, the level of TGF-β1 significantly decreased. After 6 months, there was the same trend, not reaching statistical significance. The IgG4 level and the IgG4/IgG ratio increased to 6 and 12 months, which corresponded to an increase in diplopia index.
CONCLUSION
CONCLUSIONS
The main limiting factor in the conduct of RAIT is the activity of the autoimmune process in the orbits. Since patients with inactive (CAS 0-2) or low activity (CAS 3-4) GO were referred for RAIT, there was no pronounced activation of GO after RAIT. There was a slight deterioration in the course of GO by only 1-2 points according to CAS after 3 months. (32.5%) and to a lesser degree after 6 months (13.2%). In the study, it was found that the main predictors of the deterioration of the course of GO after RAIT are uncompensated hypothyroidism, a high level of rTSH-Ab and a decrease in the level of cytokine TGF-β1.
Identifiants
pubmed: 37968948
doi: 10.14341/probl13293
pmc: PMC10680543
doi:
Substances chimiques
Iodine-131
0
Iodine Radioisotopes
0
Transforming Growth Factor beta1
0
Immunoglobulin G
0
Types de publication
English Abstract
Journal Article
Langues
rus
Sous-ensembles de citation
IM
Pagination
16-24Références
Eur Thyroid J. 2018 Aug;7(4):167-186
pubmed: 30283735
Thyroid. 2010 Jul;20(7):777-83
pubmed: 20578901
J Clin Endocrinol Metab. 2015 Jul;100(7):2700-8
pubmed: 25965082
Probl Endokrinol (Mosk). 2020 Oct 01;66(5):15-23
pubmed: 33369369
Endokrynol Pol. 2014;65(5):348-56
pubmed: 25301484
Thyroid. 2013 May;23(5):620-5
pubmed: 23205939
J Clin Endocrinol Metab. 2016 Jul;101(7):2711-20
pubmed: 27055083
J Clin Endocrinol Metab. 2006 Sep;91(9):3464-70
pubmed: 16835285
J Clin Endocrinol Metab. 2009 Oct;94(10):3700-7
pubmed: 19723755
Clin Endocrinol (Oxf). 2004 Nov;61(5):612-8
pubmed: 15521965
J Clin Endocrinol Metab. 2005 Sep;90(9):5321-3
pubmed: 15985483
Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67
pubmed: 34297684
Thyroid. 2010 Jul;20(7):785-93
pubmed: 20578895
N Engl J Med. 1992 Jun 25;326(26):1733-8
pubmed: 1489388
Clin Endocrinol (Oxf). 2008 Dec;69(6):943-50
pubmed: 18429949
Saudi J Ophthalmol. 2011 Jan;25(1):3-13
pubmed: 23960897
PLoS One. 2020 Jan 13;15(1):e0226495
pubmed: 31929534
Exp Clin Endocrinol Diabetes. 2014 Feb;122(2):113-7
pubmed: 24554511